Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|June 27, 2025
Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort studyMiao Xue, Yanqin Wu, Yiyang Tang, et al.
Acta Pharmaceutica Sinica. B|March 6, 2023
Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinomaJizhou Tan, Ting Liu, Wenzhe Fan, et al.
Gut|December 2, 2020
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cellsTing Liu, Jizhou Tan, Minhao Wu, et al.
United European Gastroenterology Journal|February 19, 2024
Locoregional therapies for hepatocellular carcinoma: The current status and future perspectivesJian-Jian Chen, Zhi-Cheng Jin, Bin-Yan Zhong, et al.
Cell Reports. Medicine|January 21, 2026
CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonistTing Liu, Huixin Gao, Zhihui Xi, et al.
Cancer Research|October 21, 2010
F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivoIra Winer, Shouyan Wang, Yong-Eun Koo Lee, et al.
Cancer Medicine|July 6, 2024
DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysisWenzhe Fan, Xinlin Zheng, Xiao Zhao, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2025
Combination locoregional and systemic therapies in hepatocellular carcinomaBin-Yan Zhong, Wenzhe Fan, Justin J Guan, et al.
Frontiers in Immunology|June 27, 2022
Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent CohortsGuosheng Yuan, Fuli Xie, Yangda Song, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2022
Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolizationWenzhe Fan, Bowen Zhu, Xinlin Zheng, et al.
Pageof 10